A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2013
At a glance
- Drugs GSK 257049 (Primary) ; AS01B; AS02; Rabies vaccine
- Indications Malaria; Rabies
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 10 Feb 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 23 Oct 2010 New trial record